Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy
Tóm tắt
Từ khóa
Tài liệu tham khảo
Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet., 395, 1054, 10.1016/S0140-6736(20)30566-3
Ruan, 2020, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med., 1
Han, 2020, Prominent changes in blood coagulation of patients with SARS-CoV-2 infection, Clin. Chem. Lab. Med., 10.1515/cclm-2020-0188
Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5
Chen, 2020, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet., 395, 507, 10.1016/S0140-6736(20)30211-7
Tang, 2020, Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J. Thromb. Haemost.
Varga, 2020
Clerkin, 2020, Coronavirus disease 2019 (COVID-19) and cardiovascular disease, Circulation.
Klok, 2020, Incidence of thrombotic complications in critically ill ICU patients with COVID-19, Thromb. Res.
Cui, 2020, Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia, J. Thromb. Haemost., 10.1111/jth.14830
Toh CH, Hoots WK, ISTH SSCoDICot. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J. Thromb. Haemost. 2007;5(3):604–6.
Samama, 1999, A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group, N. Engl. J. Med., 341, 793, 10.1056/NEJM199909093411103
Kaplan, 2015, VTE incidence and risk factors in patients with severe sepsis and septic shock, Chest., 148, 1224, 10.1378/chest.15-0287
Zhang, 2019, The cumulative venous thromboembolism incidence and risk factors in intensive care patients receiving the guideline-recommended thromboprophylaxis, Medicine (Baltimore), 98, 10.1097/MD.0000000000015833
Helms, 2020, High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study, Intensive Care Med., 10.1007/s00134-020-06062-x
Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J. Thromb. Haemost.
Schunemann, 2018, American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients, Blood Adv., 2, 3198, 10.1182/bloodadvances.2018022954
Lang, 2011, Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans, PLoS One, 6, 10.1371/journal.pone.0023710
Mycroft-West C et al. The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding. bioRxiv preprint doi: https://doi.org/10.1101/2020.02.29.97109.